Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.

Christian Ott; Susanne Jung; Manuel Korn; Dennis Kannenkeril; Agnes Bosch; Julie Kolwelter; Kristina Striepe; Peter Bramlage; Mario Schiffer; Roland E Schmieder

doi:10.1186/s12933-021-01358-8

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.

Christian Ott (Erstautor/-in), Susanne Jung, Manuel Korn, Dennis Kannenkeril, Agnes Bosch, Julie Kolwelter, Kristina Striepe, Peter Bramlage, Mario Schiffer, Roland E Schmieder

Klinik für Innere Medizin 4 - Nephrologie und Hypertensiologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

18 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	178
Fachzeitschrift	CARDIOVASCULAR DIABETOLOGY
Jahrgang	20
Ausgabenummer	1
DOIs	https://doi.org/10.1186/s12933-021-01358-8
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

10.1186/s12933-021-01358-8

Dieses zitieren

Ott, C., Jung, S., Korn, M., Kannenkeril, D., Bosch, A., Kolwelter, J., Striepe, K., Bramlage, P., Schiffer, M., & Schmieder, R. E. (2021). Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. CARDIOVASCULAR DIABETOLOGY, 20(1), 178. https://doi.org/10.1186/s12933-021-01358-8

@article{da019d00994e4f4ba6c719019d93e58c,

title = "Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.",

keywords = "GLOMERULAR HEMODYNAMICS, INTRARENAL HEMODYNAMICS, OVERWEIGHT PATIENTS, KIDNEY-DISEASE, NITRIC-OXIDE, DOUBLE-BLIND, NEPHROPATHY, PROGRESSION, INHIBITION, FILTRATION",

author = "Christian Ott and Susanne Jung and Manuel Korn and Dennis Kannenkeril and Agnes Bosch and Julie Kolwelter and Kristina Striepe and Peter Bramlage and Mario Schiffer and Schmieder, {Roland E}",

note = "Ott: Paracelsus Med Univ, Dept Nephrol *** Hypertens, Nurnberg, Germany;",

year = "2021",

doi = "10.1186/s12933-021-01358-8",

language = "English",

volume = "20",

pages = "178",

journal = "CARDIOVASCULAR DIABETOLOGY",

issn = "1475-2840",

publisher = " BioMed Central",

number = "1",

}

Ott, C, Jung, S, Korn, M, Kannenkeril, D, Bosch, A, Kolwelter, J, Striepe, K, Bramlage, P, Schiffer, M & Schmieder, RE 2021, 'Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.', CARDIOVASCULAR DIABETOLOGY, Jg. 20, Nr. 1, S. 178. https://doi.org/10.1186/s12933-021-01358-8

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. / Ott, Christian (Erstautor/-in); Jung, Susanne; Korn, Manuel et al.
in: CARDIOVASCULAR DIABETOLOGY, Jahrgang 20, Nr. 1, 2021, S. 178.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.

AU - Ott, Christian

AU - Jung, Susanne

AU - Korn, Manuel

AU - Kannenkeril, Dennis

AU - Bosch, Agnes

AU - Kolwelter, Julie

AU - Striepe, Kristina

AU - Bramlage, Peter

AU - Schiffer, Mario

AU - Schmieder, Roland E

N1 - Ott: Paracelsus Med Univ, Dept Nephrol *** Hypertens, Nurnberg, Germany;

PY - 2021

Y1 - 2021

KW - GLOMERULAR HEMODYNAMICS

KW - INTRARENAL HEMODYNAMICS

KW - OVERWEIGHT PATIENTS

KW - KIDNEY-DISEASE

KW - NITRIC-OXIDE

KW - DOUBLE-BLIND

KW - NEPHROPATHY

KW - PROGRESSION

KW - INHIBITION

KW - FILTRATION

U2 - 10.1186/s12933-021-01358-8

DO - 10.1186/s12933-021-01358-8

M3 - Original Article

C2 - 34481498

SN - 1475-2840

VL - 20

SP - 178

JO - CARDIOVASCULAR DIABETOLOGY

JF - CARDIOVASCULAR DIABETOLOGY

IS - 1

ER -